SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Joe E. who wrote (5872)1/11/1999 12:52:00 PM
From: Joe E.   of 6136
 
Another article today - from CDC Prevention news summary of media stories about HIV:

""Merck to Begin Trials of New AIDS Drug That's Easier to Take"
Wall Street Journal (01/11/99) P. B18
Merck said it expects this quarter to initiate early clinical
tests of its second protease inhibitor AIDS drug, which it
anticipates will have a less complex dosing and scheduling
regimen. The drug maker hopes the new generation protease
inhibitor can be taken once daily, versus the current Crixivan
schedule of two pills every eight hours or thrice daily. In
addition, Merck hopes patients will not be required to adhere to
a special diet, which is necessary with Crixivan. Merck's
improved drug would be a boon to patients struggling with the
complexity of AIDS treatments; the elaborate regimens and high
cost also inhibit treatment of HIV-infected patients in
developing nations."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News